SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Shehadeh, Lina A ^a   Yu, Kristine ^a   Wang, Liyong ^a   Guevara, Alexandra ^a   Singer, Carlos ^a   Vance, Jeffery ^a   Papapetropoulos, Spyridon ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ISOPROTEIN; RNA BINDING PROTEIN; SRRM2 PROTEIN, HUMAN;

AGED; ALTERNATIVE RNA SPLICING; AMYGDALOID NUCLEUS; ARTICLE; BLOOD; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXON; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NEUROLOGIC DISEASE; PARKINSON DISEASE; RNA GENE; SRRM2 RNA GENE; SUBSTANTIA NIGRA; UPREGULATION; ADULT; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; AMYGDALA; BIOLOGICAL MARKERS; EXONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSON DISEASE; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; SUBSTANTIA NIGRA;

EID: 77949342573     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009104     Document Type: Article

References (38)

1. Papapetropoulos S, McCorquodale D (2007) Gene Expression Profiling in Parkinson's disease: Discovery of valid biomarkers, molecular targets and biochemical pathways. Future Neurol 2: 29-38.
2. Papapetropoulos S, Ffrench-Mullen J, McCorquodale D, Qin Y, Pablo J, et al. (2006) Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease. Gene Expr 13: 205-215.
3. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, et al. (2005) An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 37: 710-717.
4. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, et al. (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111: 1543-1573.
5. Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, et al. (2005) Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol 62: 917-921.
6. Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, et al. (2006) Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 7: 139-148.
7. Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, et al. (2006) Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol Dis 21: 305-313.
8. Lesnick TG, Sorenson EJ, Ahlskog JE, Henley JR, Shehadeh L, et al. (2008) Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway. PLoS ONE 3: e1449.
9. Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B, Asteris G, Clark TW, et al. (2007) Effects of gender on nigral gene expression and parkinson disease. Neurobiol Dis 26: 606-614.
10. Bossers K, Meerhoff G, Balesar R, van Dongen JW, Kruse CG, et al. (2009) Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. Brain Pathol 19: 91-107.
11. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, et al. (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 104: 955-960.
12. Greene JG, Greenamyre JT, Dingledine R (2008) Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism. Neuroscience 152: 198-207.
13. Dreyfuss G, Kim VN, Kataoka N (2002) Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol 3: 195-205.
14. Mukherji M, Brill LM, Ficarro SB, Hampton GM, Schultz PG (2006) A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways. Biochemistry 45: 15529-15540.
15. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, et al. (2003) Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302: 2141-2144.
16. Schmutz J, Wheeler J, Grimwood J, Dickson M, Yang J, et al. (2004) Quality assessment of the human genome sequence. Nature 429: 365-368.
17. Schmucker D, Clemens JC, Shu H, Worby CA, Xiao J, et al. (2000) Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell 101: 671-684.
18. Dubey D, Ganesh S (2008) Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum Mol Genet 17: 3010-3020.
19. Gloor GB, Moretti J, Mouyal J, Keeler KJ (2000) Distinct P-element excision products in somatic and germline cells of Drosophila melanogaster. Genetics 155: 1821-1830.
20. Lynch KW, Weiss A (2001) A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J Biol Chem 276: 24341-24347.
21. Chisa JL, Burke DT (2007) Mammalian mRNA splice-isoform selection is tightly controlled. Genetics 175: 1079-1087.
22. Maragakis NJ, Dykes-Hoberg M, Rothstein JD (2004) Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol 55: 469-477.
23. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, et al. (2005) Function of alternative splicing. Gene 344: 1-20.
24. Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, et al. (1998) Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20: 589-602.
25. Catania MV, Aronica E, Yankaya B, Troost D (2001) Increased expression of neuronal nitric oxide synthase spliced variants in reactive astrocytes of amyotrophic lateral sclerosis human spinal cord. J Neurosci 21: RC148.
26. Akbarian S, Smith MA, Jones EG (1995) Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Brain Res 699: 297-304.
27. Sato N, Hori O, Yamaguchi A, Lambert JC, Chartier-Harlin MC, et al. (1999) A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue. J Neurochem 72: 2498-2505.
28. Beyer K, Domingo-Sabat M, Lao JI, Carrato C, Ferrer I, et al. (2008) Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 9: 15-23.
29. Dagata V, Cavallaro S (2004) Parkin transcript variants in rat and human brain. Neurochem Res 29: 1715-1724.
30. D'Souza I, Poorkaj P, Hong M, Nochlin D, Lee VM, et al. (1999) Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A 96: 5598-5603.
31. Tan EK, Shen H, Tan JM, Lim KL, Fook-Chong S, et al. (2005) Differential expression of splice variant and wild-type parkin in sporadic Parkinson's disease. Neurogenetics 6: 179-184.
32. Potashkin JA, Kang UJ, Loomis PA, Jodelka FM, Ding Y, et al. (2007) MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9. Brain Res 1182: 1-10.
33. McLean PJ, Hyman BT (2002) An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neurosci Lett 323: 219-223.
34. Lipscombe D (2005) Neuronal proteins custom designed by alternative splicing. Curr Opin Neurobiol 15: 358-363.
35. Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AI, et al. (1998) WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 12: 3217-3225.
36. Manley JL, Tacke R (1996) SR proteins and splicing control. Genes Dev 10: 1569-1579.
37. Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, et al. (2006) Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 7: 59.
38. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184.